Sign In  |  Register  |  About Los Altos  |  Contact Us

Los Altos, CA
September 01, 2020 1:26pm
7-Day Forecast | Traffic

  • Search Hotels in Los Altos

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

BioNTech SE - American Depositary Shares (NQ: BNTX )

113.67 +1.24 (+1.10%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about BioNTech SE - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
56 57 Next >
Week In Review: China Biopharmas Book $9 Billion In Deals During JP Morgan Conference Week
Shanghai Argo Biopharma entered 2 agreements with Novartis, out-licensing four next-gen RNAi therapeutics for $185 million upfront and a total value of $4.2 billion. Additionally, Ambrx Biopharma will... 
Via Talk Markets
BioNTech Prepares To Be Commercial Ready By 2025, Revenue Growth Expected To Return In 2025
On Tuesday, BioNTech SE (NASDAQ: BNTX) outlined priorities at the Annual J.P. 
Via Benzinga
P/E Ratio Insights for BioNTech
Via Benzinga
Week In Review: 2024 Kicks Off With Three Deals Worth A Total Of $4 Billion
Suzhou Ribo Life Science formed a collaboration with Boehringer Ingelheim in a deal that could be worth up to $2 billion. Additionally, Allorion Therapeutics has out-licensed global rights (ex-China)... 
Via Talk Markets
Strides Toward Lower Drug Costs: Florida Becomes First To Receive Nod To Import Prescription Drugs from Canada
The FDA has allowed Florida to import prescription drugs from Canada, potentially altering the landscape of how Americans access and afford their medications.  
Via Benzinga
Exposures Product Safety
Comparative Study: BioNTech And Industry Competitors In Biotechnology Industry
Via Benzinga
How Is The Market Feeling About BioNTech?
Via Benzinga
5 Value Stocks To Watch In The Healthcare Sector
Via Benzinga
Pharmaceutical Giants Brace for Showdown as Medicare Drug Price Negotiations Are Poised For 2024
2024 will mark a pivotal moment for the healthcare industry, particularly in drug pricing negotiations. 
Via Benzinga
A Look Into Healthcare Sector Value Stocks
Via Benzinga
Understanding BioNTech's Position In Biotechnology Industry Compared To Competitors
Via Benzinga
COVAX Global Initiative For COVID-19 Vaccines Comes To An End Amid Shift To Regular Programs
COVAX, the multilateral mechanism for equitable global access to COVID-19 vaccines launched in 2020, will close on 31 December 2023.&n 
Via Benzinga
Exposures COVID-19
What's Going On With BioNTech (BNTX) Shares?
BioNTech SE - ADR (NASDAQ: BNTX) shares are trading lower by 5.6% to $93.10 Wednesday afternoon. 
Via Benzinga
6 Analysts Have This to Say About BioNTech
Via Benzinga
Analyst Ratings for BioNTech
Via Benzinga
Why Is COVID-19 Vaccine Player CureVac Stock Plummeting Today?
A German court has invalidated a patent central to CureVac N.V's (NASDAQ: CVAC) lawsuit against BioNTech SE (NASDAQ: BNTX) related to seeking fair compensation for infringement of a portfolio of 
Via Benzinga
Topics Intellectual Property Lawsuit
Exposures COVID-19 Financial Intellectual Property
3 Stocks Down 30% or More This Year That Wall Street Expects to Skyrocket in 2024
Analysts think these beaten-down stocks could rebound strongly in the new year. 
Via The Motley Fool
Pfizer Issues FY24 Forecast, Joins Target Hospitality, Southwest Airlines And Other Big Stocks Moving Lower On Wednesday
U.S. stocks traded mostly higher, with the Nasdaq Composite gaining around 40 points on Wednesday. Shares of Pfizer Inc. (NYSE: PFE) shares fell sharply during Wednesday’s session after the company... 
Via Benzinga
Topics Stocks
Exposures US Equities
Pfizer Stock Tumble Steepens As Seagen Guidance Update Disappoints
Pfizer's updated 2024 revenue figures, including Seagen, undercut the consensus target. 
Via Investor's Business Daily
What's Going On With Moderna Stock Today?
Moderna Inc (NASDAQ: MRNA) announced changes to its operating model to bring focus to its short- and  
Via Benzinga
BioNTech Stock Downgraded, Analyst Reflects Concerns Over Growth and Pipeline Development
J.P. 
Via Benzinga
Lululemon To Rally Around 16%? Here Are 10 Top Analyst Forecasts For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Dell Reports Mixed Q3 Results, Joins Marvell Technology, Super Micro Computer And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures traded higher this morning, with the Dow Jones futures gaining more than 80 points on Friday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Is COVID-19 Vaccine Maker Moderna Stock Trading Lower Today?
Moderna Inc (NASDAQ: MRNA) shares slipped on Tuesday trading after the European Patent Office said a contested mRNA patent owned by Moderna is invalid, marking a victory for Pfizer Inc (NYSE: PFE) /  
Via Benzinga
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Acuitas Challenges CureVac in Legal Tussle Over COVID-19 Vaccine Technology
Biotech company Acuitas Therapeutics has filed a lawsuit in Virginia federal court against Germany-based CureVac SE (NASDAQ: CVAC), accusing it of failing to credit Acuitas on patents related to... 
Via Benzinga
Topics Intellectual Property Lawsuit
Exposures COVID-19 Financial Intellectual Property
3 Biotech Stocks You’ll Regret Not Buying Soon: November 2023
The global biotechnology market could nearly triple by 2030. Investors should consider buying these biotech stocks before they explode. 
Via InvestorPlace
Monday.Com To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page 
Via Benzinga
Week In Review: Eccogen Out-Licenses GLP-1 Agonist To AstraZeneca In $2 Billion Deal
Eccogene, a Shanghai-Boston biotech, out-licensed global rights (ex-China) for its novel small molecule GLP-1 agonist to AstraZeneca in a $2 billion blockbuster deal. Eccogene will receive $185 million... 
Via Talk Markets
Stock Market Rally Pauses As Yields Rebound; Datadog, Affirm Among Earnings Winners: Weekly Review
The major indexes ended long win streaks. Datadog led earnings winners. 
Via Investor's Business Daily
7 Underappreciated Biotech Stocks to Pick Up on the Cheap
With questions rising about the economy, investors may consider undervalued biotech stocks for their relative insulation factor. 
Via InvestorPlace
Topics Economy
Exposures Economy
< Previous 1 2 3 4 5 6 7 8 9
...
56 57 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 LosAltos.com & California Media Partners, LLC. All rights reserved.